Malignant Central Nervous System Neoplasm

cancer

Identifier: CI-CAN-00001115
Entity page: /cancer/malignant-central-nervous-system-neoplasm ↗
Edges: 3,222

Neighbours: 15 genes17 drugs10 trials
Drawn: 42 of 42 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Central Nervous System Neoplasm approved for …APPROVED_FORderived15 of 20show all (up to 200)
← approved for	Dordavipronesmall molecule FDA (US) · approved · 2025-08-06 · MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 …	—	approved	Diffuse Midline Glioma	1	Regulatory	openfda	graph →
approved for

Malignant Central Nervous System Neoplasm altered in cohorts of …ALTERED_INderived15 of 110show all (up to 200)
← altered in cohorts of	PTEN 461 / 601 cases (77 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	ATRNL1 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MYOF 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SEC23IP 456 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	BAG3 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CACUL1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	EGFR 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	EIF3A 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	INPP5F 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	MCMBP 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	PRLHR 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	SORBS1 455 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTA2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CTBP2 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →
← altered in cohorts of	CYP26C1 454 / 601 cases (76 %) · ssm · TCGA-GBM	—	—	Glioblastoma	1	Observed	gdc	graph →

Malignant Central Nervous System Neoplasm altered in cohorts of …ALTERED_INderived15 of 110show all (up to 200)

← altered in cohorts of

PTEN

461 / 601 cases (77 %) · ssm · TCGA-GBM

—

Glioblastoma

Observed

Malignant Central Nervous System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 228show all (up to 200)
→ investigated in trials for	Temozolomidesmall molecule 363 trials (117 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	363	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 139 trials (24 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	139	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 58 trials (26 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 56 trials (24 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 52 trials (13 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 52 trials (26 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Lomustinesmall molecule 49 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	49	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 49 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	49	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 43 trials (13 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 35 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 34 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 31 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 26 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 23 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 22 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Central Nervous System Neoplasm	22	Observed	clinicaltrials	graph →

Malignant Central Nervous System Neoplasm studied in …STUDIED_INderived10 of 2,864show all (up to 200)
→ studied in	NCT05685004Phase 2/Phase 3 · active not recruiting Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) · condition mapped ALIAS · 2,864 trials mapped (952 active)	—	—	Brain Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05864534Phase 2 · active not recruiting Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma · condition mapped CURATED_BROADER · 2,864 trials mapped (952 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05871021Phase 2 · active not recruiting Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma · condition mapped CURATED_BROADER · 2,864 trials mapped (952 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05902169Phase 3 · recruiting Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM · condition mapped CURATED_BROADER · 2,864 trials mapped (952 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06325683Phase 2 · suspended Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma · condition mapped CURATED_BROADER · 2,864 trials mapped (952 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07374692completed Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · condition mapped ALIAS · 2,864 trials mapped (952 active)	—	—	Malignant Brain Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07492316Phase 1 · active not recruiting RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · condition mapped CURATED_BROADER · 2,864 trials mapped (952 active)	—	—	Medulloblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01109394recruiting Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies · condition mapped ONTOLOGY_EXACT · 2,864 trials mapped (952 active)	—	—	Retinoblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01445288completed Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors · condition mapped ONTOLOGY_EXACT · 2,864 trials mapped (952 active)	—	—	Diffuse Intrinsic Pontine Glioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303467Phase 1 · recruiting A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM · condition mapped CURATED_BROADER · 2,864 trials mapped (952 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains